Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1476967 | 1.00 | GRM7 (0.44) | GRM7HCRTR2AKR1B1DRD2DRD3 | |
| SCHEMBL1476969 | 1.00 | GRM7 (0.44) | GRM7HCRTR2AKR1B1DRD2DRD3 | |
| SCHEMBL30280553 | 1.00 | GRM7 (0.44) | GRM7HCRTR2AKR1B1DRD2DRD3 | |
| SCHEMBL12749289 | 1.00 | GRM7 (0.44) | GRM7HCRTR2AKR1B1DRD2DRD3 | |
| SCHEMBL10897784 | 0.81 | GRM7 (0.47) | GRM7HCRTR2AKR1B1DRD2DRD3 | |
| SCHEMBL1478395 | 0.80 | L3MBTL1 (0.40) | GRM7HCRTR2AKR1B1ALDH1A1 | |
| SCHEMBL1478400 | 0.80 | L3MBTL1 (0.40) | GRM7HCRTR2AKR1B1ALDH1A1 | |
| SCHEMBL1478396 | 0.80 | L3MBTL1 (0.40) | GRM7HCRTR2AKR1B1ALDH1A1 | |
| SCHEMBL12749279 | 0.80 | L3MBTL1 (0.40) | GRM7HCRTR2AKR1B1ALDH1A1 | |
| SCHEMBL13591299 | 0.79 | GRM7 (0.41) | GRM7HCRTR2AKR1B1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373261-B1 | CYCLOPROPAHETEROCYCLES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2011-05-04 | — | — | EP | disclosed |
| US-7915295-B2 | Viricides; HIV antivirals effective against problematic drug escape mutants; N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-[5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| EP-1701942-B1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2009-12-09 | — | — | EP | disclosed |
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-7405310-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2008-07-29 | — | — | US | disclosed |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | MEDIVIR AB (SE) | 2008-03-20 | — | — | US | disclosed |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2006-07-27 | — | — | US | disclosed |
| US-20050240035-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2005-10-27 | — | — | US | disclosed |
| US-6894177-B2 | Intermediate compounds of non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2005-05-17 | — | — | US | disclosed |
| US-6716850-B2 | ESPECIALLY N-(NITROGEN HETEROAR-2-YL)-SUBSTITUTED TETRAHYDROCYCLOPROPA(C)CHROMEN-1-UREAS AND THIOUREAS; TREATING HIV-1, PARTICULARLY A DRUG ESCAPE MUTANT. | MEDIVIR AB (SE) | 2004-04-06 | — | — | US | disclosed |
| US-20030187266-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| US-20030069224-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240035-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, TYMP, PNP | GRM7 4111/4885HCRTR2 3874/4885AKR1B1 524/4885 |
| US-20030069224-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, NAT10, NSUN2 | GRM7 3404/4885HCRTR2 856/4885AKR1B1 1173/4885 |
| US-20030187266-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, NAT10, NSUN2 | GRM7 3404/4885HCRTR2 856/4885AKR1B1 1173/4885 |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR2H, POLR2E, POLR1E | GRM7 3084/4885HCRTR2 377/4885AKR1B1 1681/4885 |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | RCOR1, RRM2, POLR1A | GRM7 2330/4885HCRTR2 355/4885AKR1B1 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.